Letter: Confounding Factors in the Association Between Sarcopenia and Carotid Atherosclerosis Among Patients With Type 2 Diabetes Mellitus

Abstract

Get full access to this article

View all access options for this article.

References

Yang

Zhang

, et al. Sex and age influence the relationship between serum creatinine/cystatin C and carotid plaque in patients with type 2 diabetes mellitus. Angiology. 2026;77:212-220.

Kwon

Cho

Park

, et al. Effect of combination therapy with ezetimibe and statins versus statin monotherapy on carotid intima-media thickness: a systematic review and meta-analysis of randomized controlled trials. Medicina (Kaunas). 2023;59:1980.

Hetherington

Totary-Jain

Anti-atherosclerotic therapies: milestones, challenges, and emerging innovations. Mol Ther. 2022;30:3106-17.

Yang

, et al. Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2024;15:1403606.

Chen

Găman

Tan

Zhu

The effect of metformin on carotid intima-media thickness (CIMT): a systematic review and meta-analysis of randomized clinical trials. Eur J Pharmacol. 2020;886:173458.

Scisciola

Cataldo

Taktaz

, et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials. Front Cardiovasc Med. 2022;9:1008922.

Akbari

Hadizadeh

Heidary

Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on intima-media thickness: systematic review and meta-analysis. J Diabetes Res. 2024;2024:3212795.

Mita

Katakami

Yoshii

, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care. 2016;39:139-48. Erratum in: Diabetes Care. 2017;40:808.

Gao

Lin

Can proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors regress coronary atherosclerotic plaque? A systematic review and meta-analysis. Am J Transl Res. 2023;15:452-65.

10.

Marfella

Prattichizzo

Sardu

, et al. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Atherosclerosis. 2023;378:117180.

11.

Fujino

Di Giovanni

Nicholls

. New approaches to lipoproteins for the prevention of cardiovascular events. J Atheroscler Thromb. 2025;32:265-80.

12.

Velasco

Rojas

Pirela

VB.

Approach to a successful selection of antihypertensive drugs for the patient with atherosclerosis. Am J Ther. 2013;20:442-7.

13.

Williams

Han

Takagi

, et al. Effects of renin-angiotensin-aldosterone-system inhibitors on coronary atherosclerotic plaques: the PARADIGM registry. Atherosclerosis. 2023;383:117301.

14.

Sana

Chaudhry

Malik

Iqbal

Zakiuddin

Abdullah

Prevalence of microalbuminuria in type 2 diabetes mellitus. Cureus. 2020;12:e12318.

15.

Szabóová

Lisovszki

Fatľová

Kolarčik

Szabó

Molnár

Prevalence of microalbuminuria and its association with subclinical carotid atherosclerosis in middle aged, nondiabetic, low to moderate cardiovascular risk individuals with or without hypertension. Diagnostics (Basel). 2021;11:1716.